Can it postpone knee replacement?

Possibly. The best available evidence suggests that intra-articular hyaluronic acid (HA) is associated with a later move to total knee replacement in some people with knee osteoarthritis, rather than showing that it reliably stops surgery altogether. In the 2015 U.S. claims study by Altman and colleagues, which identified 182,022 patients who eventually had total knee replacement, half of HA non-users reached surgery by 114 days after diagnosis, compared with 484 days in HA users. A 2022 systematic review and meta-analysis reported a similar direction of effect, estimating an average 9.8-month longer interval from knee osteoarthritis diagnosis to knee replacement in patients who received HA.

That is a meaningful signal, but it is still an association. The Altman paper was retrospective and based on administrative claims data from a database covering roughly 79 million patients, so it cannot prove that HA itself caused the delay; patients who chose injections may also have differed in symptom severity, timing, access to care, or willingness to postpone an operation. In practical terms, HA is a viscosupplement used for symptom control, not a cartilage-repair treatment, so the realistic expectation is that it may buy time in selected cases rather than prevent knee replacement altogether.

How much delay do studies show?

Rather than replay the opening comparison, the more useful detail is the pattern behind it: the reported delay is usually measured in months, not just weeks. In Altman et al. in 2015, the signal was not simply that surgery happened later on average. Mean time to total knee replacement was 0.7 years in patients with no HA and 1.4 years after one HA course, with additional courses associated with progressively longer intervals. That dose-response pattern does not prove that HA caused the delay, but it does make the association harder to dismiss as random noise.

The same general direction shows up elsewhere. A 2018 real-world study of repeated HA courses reported that repeated treatment was associated with delaying total knee replacement for up to 3 years, while also saying that more research was needed on repeated-treatment effects. In 2022, a systematic review and meta-analysis pooled the available studies and found that HA use was associated with an interval about 9.8 months longer before knee replacement. Taken together, the practical takeaway is often months, and in some cohorts longer, rather than a fixed extra number of weeks.

Those figures still need careful handling. The 2022 meta-analysis measured time from declared knee osteoarthritis diagnosis to surgery, whereas claims studies and repeated-course analyses may track timing in relation to treatment exposure or treatment cycles. Mean and median numbers describe groups, not what every individual patient will experience. Some patients still move to knee replacement relatively quickly after injections, while others may defer surgery for much longer.

Why postponing surgery changes the cost picture

The cost argument changes once total knee arthroplasty is treated as the main cost event rather than just the end of the treatment pathway. In a U.S. Medicare analysis, mean knee-osteoarthritis-related cost in the hyaluronic-acid group was $23,393 for patients who went on to arthroplasty, compared with $3,398 for those who did not. The same AHDB report says knee osteoarthritis accounts for more than $27 billion in annual healthcare costs in the United States, with total knee arthroplasty alone exceeding $11 billion. That helps explain why HA can look economically favourable even without changing the underlying disease: presurgical treatments are a relatively small share of spend, while the operation is the expensive step that dominates the ledger.

That pattern is broadly what the 2021 U.S. systematic review of economic evaluations found. Mordin and colleagues reported that intra-articular HA generally appeared cost-effective in the included analyses and was associated with lower arthroplasty use through about 2 years of follow-up. The important limit is in their own conclusion: it remained unclear whether the saving holds up over the long term if surgery is merely delayed rather than avoided. In other words, HA may look financially sensible in models where postponing a high-cost operation has value, but that is not the same as proving durable lifetime savings.

Because these figures come from U.S. claims, Medicare and reimbursement data, the exact dollar amounts do not transfer neatly to the UK. The underlying principle probably travels better than the headline numbers: when knee replacement is the biggest cost item, even a modest postponement can materially improve short-term cost calculations.

Why specialists still speak cautiously

The useful caution here is not to replay the delay figures already covered, but to look at what sort of evidence produced them. Much of the literature behind the apparent delay signal — including Altman et al. 2015 and a 2018 repeated-courses study — comes from retrospective claims or other real-world analyses, not randomised trials built to test whether an injection prevents knee replacement. That makes the signal clinically interesting, but it also means the evidence is better at showing association than proving cause.

In routine practice, patients who receive HA are not a random cross-section of everyone with knee osteoarthritis. In a U.S. claims database, they may reach treatment earlier, have less advanced joint damage, have different insurance access, be more willing to keep trying non-operative care, or be under surgeons who are comfortable delaying arthroplasty. Any of those factors could lengthen the path to surgery. So an observed “delay” may reflect patient selection and care patterns as well as any effect of HA itself.

Symptom benefit is another reason specialists stay measured. AAOS patient guidance says recent research has not shown viscosupplementation to significantly reduce pain or improve function overall, and it adds that some patients report relief while others do not. If pain and function gains are inconsistent, it becomes harder to argue that HA reliably replaces a definitive operation.

The practical conclusion is therefore narrower than the headline question. The 2021 U.S. economic review found IAHA could appear cost-effective and was associated with lower arthroplasty use over about 2 years, but it also noted uncertainty once surgery is delayed rather than avoided. The best-supported claim is that HA may postpone knee replacement in some real-world settings; it has not been shown to reliably prevent or substitute for arthroplasty.

Who may still consider an HA injection

In practice, the patients most likely to consider an HA injection are those with symptomatic knee osteoarthritis who want a time-buying measure rather than an immediate total knee replacement. That often includes people who are not yet ready for surgery, are not medically optimised for an operation, or want a window to pursue exercise-based rehabilitation, weight reduction and other non-operative care. AAOS guidance is useful for setting expectations here: recent research has not shown viscosupplementation to significantly improve pain or function overall, and response is inconsistent, with some patients reporting relief and others not improving.

A reasonable discussion point is whether HA helped enough the first time to justify another course. In a 2018 real-world study, repeated HA courses were reported as safe and were associated with delaying knee replacement for up to 3 years, but the authors also said more research was needed on repeated-treatment effects. That is probably the fairest way to frame it in clinic: repeated courses may be discussed in selected patients, but not every patient will gain a meaningful delay, and HA should not be treated as a guaranteed bridge away from surgery.

Its role narrows when arthritis is already so advanced that the overall pathway is clearly heading towards knee replacement. HA does not repair cartilage and should not be sold as a regenerative treatment. At best, it may ease symptoms and, in some cases, buy time; it is less likely to alter the endpoint when the joint is already at the stage where replacement is the obvious next step.

What to ask before deciding

Useful questions in clinic include:

• Is the aim "pain relief", better walking or stairs, or simply "buying time" before knee replacement? HA tends to make more sense when the goal is symptom control or a short pause, not cartilage repair.
• Given the X-ray or MRI, how likely is HA to help at this stage of arthritis, and what would count as a "meaningful response" after the injection? AAOS notes that some patients improve and others do not.
• If the first injection helps, would a repeat course realistically be discussed, or would that be unlikely in this knee? A 2018 real-world study suggested repeated courses may delay surgery in some cases, but also called for more research.
• What are the likely "self-pay" costs now, and which alternatives should sit beside HA in the comparison — physiotherapy, weight-loss support, analgesia, PRP, or moving on to surgical opinion?

The endpoint is the decision itself: if symptoms, prior non-operative treatment, and X-ray or MRI findings still leave room for a time-buying step, HA may be reasonable; if severe pain, loss of function and advanced joint change all point the same way, knee replacement is often the more realistic next move.